The following
prostate cancer trials have been conducted, among others: • EORTC 30761 –
cyproterone acetate 250 mg/day versus
medroxyprogesterone acetate 200 mg/day versus
diethylstilbestrol 3 mg/day • EORTC 30762 –
estramustine phosphate 280 mg/day (560 mg/day initially) versus
diethylstilbestrol 3 mg/day • EORTC 30843 – orchiectomy versus
buserelin versus buserelin plus cyproterone acetate (150 mg/day) • EORTC 30853 – orchiectomy versus
goserelin plus flutamide (750 mg/day) • EORTC 30892 – flutamide monotherapy (750 mg/day) versus
cyproterone acetate (300 mg/day) • EORTC 30903 –
prednisone versus
flutamide • EORTC 30958 – intermittent
combined androgen blockade == References ==